Development and validation of an LC–MS/MS assay for the quantification of efavirenz in different biological matrices | Zendy

Paul Curley | Zendy; Marco Siccardi | Zendy; Darren Moss | Zendy; Andrew Owen | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Development and validation of an LC–MS/MS assay for the quantification of efavirenz in different biological matrices

Author(s) -

Paul Curley,

Marco Siccardi,

Darren Moss,

Andrew Owen

Publication year - 2016

Publication title -

bioanalysis

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.566

H-Index - 58

eISSN - 1757-6199

pISSN - 1757-6180

DOI - 10.4155/bio-2016-0021

Subject(s) - efavirenz , reverse transcriptase inhibitor , in vivo , chemistry , pharmacology , chromatography , pharmacokinetics , bioanalysis , reverse transcriptase , human immunodeficiency virus (hiv) , antiretroviral therapy , medicine , biology , virology , rna , viral load , biochemistry , microbiology and biotechnology , gene

The non-nucleoside reverse transcriptase inhibitor efavirenz is one of the most prescribed antiretroviral therapeutics. Efavirenz-containing therapy has become associated with the occurrence of CNS side effects, including sleep disturbances, depression and even psychosis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research